Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 8/20 | 0.70 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989518 | 0.98 | — | — | |
| SCHEMBL25389365 | 0.88 | CPN1 (0.68) | CPN1CPB2PTGS1SLC7A11CYP2C9 | |
| SCHEMBL2353967 | 0.83 | CPN1 (1.00) | CPN1CPB2 | |
| SCHEMBL9063708 | 0.76 | — | — | |
| SCHEMBL2354051 | 0.76 | CPN1 (1.00) | CPN1CPB2 | |
| SCHEMBL3179113 | 0.75 | — | — | |
| SCHEMBL2349599 | 0.74 | CPN1 (1.00) | CPN1CPB2CYP2C9CYP2C19HIF1A | |
| SCHEMBL2352986 | 0.74 | CPN1 (1.00) | CPN1CPB2 | |
| Lithium Ion SCHEMBL4370616 | 0.74 | CPN1 (0.47) | CPN1CPB2 | |
| SCHEMBL11369626 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185517-B1 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF | MOEHS IBERICA SL (ES) | 2012-09-19 | — | — | EP | disclosed |
| US-8163924-B2 | Process for preparing a leukotriene antagonist and an intermediate thereof | Moehs Ibérica, S.L. (ES) | 2012-04-24 | — | — | US | disclosed |
| US-20100204476-A1 | Process for preparing a leukotriene antagonist and an intermediate thereof | MOEHS IBERICA S.L. (ES) | 2010-08-12 | — | — | US | disclosed |
| EP-2185517-A1 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF | Moehs Ibérica, S.L. (ES) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016191-A1 | PROCESS FOR PREPARING A LEUKOTRIENE ANTAGONIST AND AN INTERMEDIATE THEREOF | Moehs Ibérica, S.L. (ES) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204476-A1 | Process for preparing a leukotriene antagonist and an intermediate thereof | CYSLTR2, LTB4R2, LTA4H | CPN1 2919/4885CPB2 1403/4885PTGS1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.